Artelo Biosciences Current Ratio Growth & History (ARTL)

Artelo Biosciences's current ratio was 0.17 for fiscal 2025.

View full Artelo Biosciences company overview

Artelo Biosciences annual current ratio history

Artelo Biosciences annual current ratio

Fiscal yearPeriod endedCurrent ratioChangeGrowth
20252025-12-310.17−1.27−88.09%
20242024-12-311.44−7.06−83.03%
20232023-12-318.51−9.85−53.67%
20222022-12-3118.36−5.60−23.38%
2021 · Dec 312021-12-3123.96
2021 · Aug 312021-08-3119.6114.95+320.48%
20202020-08-314.660.32+7.26%
20192019-08-314.353.60+483.59%
20182018-08-310.75−18.76−96.18%
20172017-08-3119.5119.30+9349.67%
20162016-08-310.21−9.59−97.89%
20152015-08-319.79

Artelo Biosciences current ratio trends

Between the periods ended 2015-08-31 and 2025-12-31, Artelo Biosciences's current ratio decreased from 9.79 to 0.17, a change of −9.62. The latest reported quarter, Q2 2026, shows 3.00.

About the metric

What the current ratio means

The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.

Calculation and source

How the current ratio is calculated

TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Artelo Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about ARTL yet. Start the conversation.

Write the first post